{"schema_version":"secwatch.filing_event.v1","accession":"0001731122-24-001845","form_type":"8-K","ticker":null,"cik":"0001708331","company_name":"Virpax Pharmaceuticals, Inc.","filed_at":"2024-11-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.298218+00:00","generated_at":"2026-05-29T19:49:42.184532+00:00","sec_items":["3.01","5.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Virpax resolves Nasdaq delisting, appoints new director, extends NIH collaboration, posts positive Probudur results","bullets":["On Nov 19, Virpax cured Nasdaq delisting notice by appointing Esha Randhawa as independent director and audit committee member.","CEO Jatinder Dhaliwal entered contractor agreement; annual fee $200k plus milestone incentives tied to IND, trials, FDA approval.","NIH/NCATS extended collaboration for NES100 intranasal enkephalin pain candidate, aiming for IND for acute/chronic non-cancer pain.","Probudur minipig DRF study showed positive tolerance, no adverse effects; supports IND filing for long-acting bupivacaine formulation."],"urls":{"canonical":"https://secwatch.observer/filing/0001731122-24-001845","json":"https://secwatch.observer/filing/0001731122-24-001845.json","markdown":"https://secwatch.observer/filing/0001731122-24-001845.md","text":"https://secwatch.observer/filing/0001731122-24-001845.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708331/000173112224001845/0001731122-24-001845-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708331/000173112224001845/e6163_8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T19:49:42.184532+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2f9f90bd31","claim":"Esha Randhawa was appointed as Independent Director at Virpax Pharmaceuticals, Inc..","evidence_excerpt":"on November 19, 2024, the Board appointed Ms. Esha Randhawa to serve as an independent director of the Company, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1708331/000173112224001845/0001731122-24-001845-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Independent Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}